Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 8 | 2021 | 671 | 2.400 |
Why?
|
| Homes for the Aged | 4 | 2021 | 157 | 1.320 |
Why?
|
| Long-Term Care | 5 | 2021 | 177 | 1.080 |
Why?
|
| Body Mass Index | 3 | 2019 | 864 | 1.010 |
Why?
|
| Atrial Fibrillation | 4 | 2021 | 836 | 1.000 |
Why?
|
| Obesity | 6 | 2019 | 1230 | 0.960 |
Why?
|
| Anticoagulants | 4 | 2021 | 495 | 0.940 |
Why?
|
| Stroke | 3 | 2021 | 1190 | 0.790 |
Why?
|
| Skilled Nursing Facilities | 1 | 2019 | 83 | 0.580 |
Why?
|
| Accidental Falls | 2 | 2020 | 128 | 0.580 |
Why?
|
| Hip Fractures | 1 | 2018 | 77 | 0.550 |
Why?
|
| Overweight | 2 | 2018 | 249 | 0.510 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 57 | 0.500 |
Why?
|
| Activities of Daily Living | 4 | 2021 | 294 | 0.500 |
Why?
|
| Medical Informatics | 1 | 2016 | 72 | 0.480 |
Why?
|
| Quality of Health Care | 2 | 2016 | 517 | 0.470 |
Why?
|
| Patient Admission | 1 | 2016 | 190 | 0.450 |
Why?
|
| Aged | 11 | 2021 | 14273 | 0.400 |
Why?
|
| United States | 8 | 2021 | 7745 | 0.380 |
Why?
|
| Risk Factors | 6 | 2021 | 5309 | 0.370 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 5413 | 0.360 |
Why?
|
| Medicaid | 1 | 2014 | 359 | 0.340 |
Why?
|
| Risk Assessment | 3 | 2021 | 2045 | 0.250 |
Why?
|
| Male | 11 | 2021 | 29546 | 0.250 |
Why?
|
| Female | 11 | 2021 | 32560 | 0.230 |
Why?
|
| Humans | 14 | 2021 | 62866 | 0.220 |
Why?
|
| Age Factors | 2 | 2021 | 1556 | 0.220 |
Why?
|
| Retrospective Studies | 4 | 2021 | 6549 | 0.220 |
Why?
|
| Leydig Cells | 2 | 2012 | 12 | 0.180 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 163 | 0.170 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 160 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2021 | 267 | 0.160 |
Why?
|
| Observation | 1 | 2019 | 30 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2020 | 210 | 0.150 |
Why?
|
| Thinness | 1 | 2018 | 44 | 0.150 |
Why?
|
| Models, Economic | 1 | 2018 | 44 | 0.150 |
Why?
|
| Comorbidity | 1 | 2021 | 1119 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 352 | 0.140 |
Why?
|
| Health Expenditures | 1 | 2018 | 122 | 0.130 |
Why?
|
| Medicare | 1 | 2021 | 614 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2018 | 307 | 0.130 |
Why?
|
| Hospitalization | 2 | 2021 | 1346 | 0.130 |
Why?
|
| New York | 1 | 2016 | 144 | 0.120 |
Why?
|
| Prevalence | 1 | 2019 | 1366 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 775 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2019 | 505 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2016 | 497 | 0.120 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 97 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2014 | 34 | 0.110 |
Why?
|
| Weight Gain | 1 | 2015 | 170 | 0.110 |
Why?
|
| Time Factors | 1 | 2021 | 3749 | 0.110 |
Why?
|
| Luteinizing Hormone | 2 | 2012 | 99 | 0.110 |
Why?
|
| Testis | 2 | 2012 | 141 | 0.100 |
Why?
|
| Postpartum Period | 1 | 2015 | 195 | 0.100 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2012 | 5 | 0.100 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2012 | 28 | 0.100 |
Why?
|
| Receptors, Peptide | 1 | 2012 | 34 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2018 | 2549 | 0.100 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2012 | 66 | 0.090 |
Why?
|
| Health Status | 1 | 2014 | 433 | 0.090 |
Why?
|
| Sex Factors | 1 | 2014 | 975 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2021 | 5598 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 378 | 0.080 |
Why?
|
| Androgens | 1 | 2010 | 48 | 0.080 |
Why?
|
| Sexual Maturation | 1 | 2010 | 51 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2012 | 1348 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2652 | 0.070 |
Why?
|
| Middle Aged | 2 | 2018 | 17390 | 0.060 |
Why?
|
| RNA, Ribosomal | 1 | 2003 | 56 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 3263 | 0.050 |
Why?
|
| Polypharmacy | 1 | 2020 | 61 | 0.040 |
Why?
|
| Mobility Limitation | 1 | 2020 | 49 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 875 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2003 | 708 | 0.040 |
Why?
|
| China | 1 | 2018 | 169 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 194 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1115 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 853 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 331 | 0.030 |
Why?
|
| Pregnancy | 2 | 2015 | 2326 | 0.030 |
Why?
|
| Psychology | 1 | 2015 | 44 | 0.030 |
Why?
|
| Anthropometry | 1 | 2015 | 86 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 173 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1541 | 0.030 |
Why?
|
| Gestational Age | 1 | 2015 | 189 | 0.030 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2012 | 4 | 0.030 |
Why?
|
| Androstenedione | 1 | 2012 | 8 | 0.020 |
Why?
|
| Activin Receptors, Type I | 1 | 2012 | 14 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 130 | 0.020 |
Why?
|
| Testosterone | 1 | 2012 | 119 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 573 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 318 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2010 | 1534 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2012 | 219 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2010 | 18 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2010 | 150 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 1623 | 0.020 |
Why?
|
| Steroids | 1 | 2010 | 54 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 147 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 545 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 890 | 0.020 |
Why?
|
| Mice | 2 | 2012 | 10815 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 2104 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 1273 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 1980 | 0.020 |
Why?
|
| Aging | 1 | 2010 | 743 | 0.010 |
Why?
|
| Chaperonins | 1 | 2003 | 6 | 0.010 |
Why?
|
| Endopeptidase Clp | 1 | 2003 | 35 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 64 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 20612 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2003 | 78 | 0.010 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2003 | 58 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2003 | 300 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 1335 | 0.010 |
Why?
|
| Escherichia coli Proteins | 1 | 2003 | 271 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 672 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1997 | 0.010 |
Why?
|
| Adult | 1 | 2015 | 16668 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2003 | 769 | 0.010 |
Why?
|